Ignite Creation Date:
2024-05-05 @ 11:48 AM
Last Modification Date:
2024-10-26 @ 9:14 AM
Study NCT ID:
NCT00139373
Status:
UNKNOWN
Last Update Posted:
2007-09-14
First Post:
2005-08-30
Brief Title:
Study of the Distractibility Syndrome in Patients With Progressive Supranuclear Palsy
Sponsor:
Groupe Hospitalier Pitie-Salpetriere
Organization:
Groupe Hospitalier Pitie-Salpetriere
Study Overview
Official Title:
Study of the Distractibility Syndrome in Patients With Progressive Supranuclear Palsy
Status:
UNKNOWN
Status Verified Date:
2005-07
Last Known Status:
RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The syndrome of distractibility is a behavioral disorder induced by a lesion or a dysfunction of the frontal lobe This sign is frequent in patients with progressive supranuclear palsy PSP a neurodegenerative disorder with severe neuronal loss in the prefrontal cortex and cholinergic systems in particular in the Meynert basalis nucleus This could participate in the occurrence of the distractibility in these patients The aim of this study is to evaluate the effect of the donepezil an anticholinesterase on the distractibility in PSP patients by using oculomotor and neuropsychological assessments
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None